PF-Atlas › Clinical Trials › NCT04300920
Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection Trial
N-acetyl cysteine · Phase 3
Registry ID
NCT04300920
Phase
Phase 3
Status
Completed
Drug / intervention
N-acetyl cysteine
Sponsor
Fernando J Martinez
Start
2020-12-17
Enrollment
202
Locations
25
About this trial
The purpose of this study is to compare the effect of n-acetylcysteine (NAC) plus standard care with matched placebo plus standard of care in patients diagnosed with idiopathic pulmonary fibrosis (IPF) who have the TOLLIP rs3750920 TT genotype. The study will compare the time to a composite endpoint of relative decline in lung function \[10% relative decline in forced vital capacity (FVC), first respiratory hospitalization, lung transplantation, or all-cause mortality\] The secondary objectives will be to examine the effect of NAC on the components of the primary composite endpoint, the rates of clinical events, change in physiology, change in health status, and change in respiratory symptoms.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT04300920 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.